9786200080943 - Registration Process of Generic Budesonide DPI as per USFDA Guidelines: Dossier Submission of Budesonide Dry Powder Inhaler with the application of eCTD Software di... (15 risultati)

Paperback. Condizione: Good. Somewhat damaged. May have bumped corner, torn dust cover, folded pages, light dust soil, remainder mark, price sticker, other damage, or be bent. 99% of orders arrive in 4-10 days. Discounted shipping on multiple books.

Condizione: New.

Condizione: As New. Unread book in perfect condition.

Condizione: New. In.

Paperback. Condizione: New.

Condizione: New.

Condizione: As New. Unread book in perfect condition.

Taschenbuch. Condizione: Neu. Registration Process of Generic Budesonide DPI as per USFDA Guidelines | Dossier Submission of Budesonide Dry Powder Inhaler with the application of eCTD Software | Hansal Gandhi | Taschenbuch | 136 S. | Englisch | 2019 | LAP LAMBERT Academic Publishing | EAN 9786200080943 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | Anbieter: preigu.

paperback. Condizione: New. New. book.

PAP. Condizione: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

PAP. Condizione: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -The purpose of this book is to develop a hypothetical dossier based on regulations and guidances which are required to be followed when an actual submission is filed to the USFDA, with an objective to meet the Common Technical Document(CTD) requirements. For this purpose, Budesonide Dry Powder Inhaler(DPI) is selected as a product to prepare a hypothetical dossier. In terms of volume by 2026 it is expected that requirement of DPI in USA would be increased and may reach up to 400 million units per year due to increasing air pollution and increased rate of respiratory diseases in children as well as old age people. In this study an ANDA has been prepared which includes data of the different modules such as Module 1: Administrative Information, Module 2: Quality Overall Summary, Module 3: Quality (Drug substance and Drug product) and Module 5: Clinical Study Reports. To get the ANDA approval, generic applicants has to show scientific evidence that their product is bioequivalent to the innovators drug product. Once the application is submitted it will undergo through a thorough review process by CDER, OGD & OCP and if they find it satisfactory, product will get approval from FDA. 136 pp. Englisch.

Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Gandhi HansalHansal Gandhi is dedicated, detail oriented and goal driven professional with broad proficiencies in Regulatory Affairs. He has completed his Masters of Pharmacy in the field of Pharmaceutical Regulatory Affairs and has .

Taschenbuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -The purpose of this book is to develop a hypothetical dossier based on regulations and guidances which are required to be followed when an actual submission is filed to the USFDA, with an objective to meet the Common Technical Document(CTD) requirements. For this purpose, Budesonide Dry Powder Inhaler(DPI) is selected as a product to prepare a hypothetical dossier. In terms of volume by 2026 it is expected that requirement of DPI in USA would be increased and may reach up to 400 million units per year due to increasing air pollution and increased rate of respiratory diseases in children as well as old age people. In this study an ANDA has been prepared which includes data of the different modules such as Module 1: Administrative Information, Module 2: Quality Overall Summary, Module 3: Quality (Drug substance and Drug product) and Module 5: Clinical Study Reports. To get the ANDA approval, generic applicants has to show scientific evidence that their product is bioequivalent to the innovators drug product. Once the application is submitted it will undergo through a thorough review process by CDER, OGD & OCP and if they find it satisfactory, product will get approval from FDA.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 136 pp. Englisch.

Taschenbuch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - The purpose of this book is to develop a hypothetical dossier based on regulations and guidances which are required to be followed when an actual submission is filed to the USFDA, with an objective to meet the Common Technical Document(CTD) requirements. For this purpose, Budesonide Dry Powder Inhaler(DPI) is selected as a product to prepare a hypothetical dossier. In terms of volume by 2026 it is expected that requirement of DPI in USA would be increased and may reach up to 400 million units per year due to increasing air pollution and increased rate of respiratory diseases in children as well as old age people. In this study an ANDA has been prepared which includes data of the different modules such as Module 1: Administrative Information, Module 2: Quality Overall Summary, Module 3: Quality (Drug substance and Drug product) and Module 5: Clinical Study Reports. To get the ANDA approval, generic applicants has to show scientific evidence that their product is bioequivalent to the innovators drug product. Once the application is submitted it will undergo through a thorough review process by CDER, OGD & OCP and if they find it satisfactory, product will get approval from FDA.